Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Secondary skull base malignancies in survivors of retinoblastoma: the memorial sloan kettering cancer center experience.
Authors: Liu JC,  Givi B,  Wolden S,  Kleinerman RA,  Dunkel IJ,  Lee N,  Shah JP,  Abramson DH,  Kraus DH
Journal: Skull Base
Date: 2011 Mar
Branches: REB
PubMed ID: 22451810
PMC ID: PMC3312595
Abstract: We report the pathology and outcome of secondary skull base tumors in patients previously treated with external beam radiation for retinoblastoma (Rb). Rb patients are at increased risk of second head and neck primary malignancies due to early radiation exposure during treatment and loss of RB1 protein in genetic carriers. An institutional database was reviewed for patients with retinoblastoma who had previously received radiation therapy and subsequently developed skull base tumors. Seventeen patients met the selection criteria. The median age of Rb diagnosis was 12 months. Thirteen cases underwent enucleation in addition to radiation therapy as part of initial Rb treatment. A median of 19 years elapsed between the diagnosis of Rb and diagnosis of skull base malignancy. The most common tumors were osteogenic sarcoma (39%) and leiomyosarcoma (22%). Eleven (71%) patients received postoperative chemotherapy, and 7 (41%) received postoperative radiotherapy. Three (24%) patients underwent salvage surgery for recurrent disease. Five-year survival was 68%, and 10-year survival was 51% by Kaplan-Meier analysis. Secondary malignancy in Rb patients is a well-defined event. The use of surgery with appropriate adjuvant therapy was associated with a 51% 10-year survival in this study population.